Why the Mesoblast share price gained 58% in the first half of 2020

The Mesoblast share price gained more than 58% in the first half of 2020, we take a look at what was driving those gains

| More on:
wooden blocks with percentage signs being built into towers of increasing height

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mesoblast limited (ASX: MSB) share price performed exceptionally well during the first half of 2020. This is not entirely surprising given Mesoblast is engaging in the development of biologic products for regenerative medicine during a global pandemic.

Across the first half of the year, the Mesoblast share price rose from $2.05 to $3.25 on 30 June. That represents a rise of 58.5% which is pretty impressive considering the time frame. The Mesoblast share price spiked as high as $4.45 and fell as low as $1.02 in what was an incredibly volatile 6 months for the biotech stock.

What does Mesoblast do?

Mesoblast uses its proprietary technology platform to develop and commercialise innovative allogeneic cellular medicines to treat complex diseases. The company targets diseases that are resistant to a conventional standard of care and where inflammation plays a central role.

Mesoblast has four phase 3 products nearing registration:

  • Revascor for advanced chronic heart failure
  • MPC-06-ID for chronic low back pain due to degenerative disc disease
  • Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection
  • Ryoncil for use in steroid-refractory acute host disease

What's been moving the Mesoblast share price this year?

With COVID-19 still rampant across the globe, it is likely that the rise of the Mesoblast share price is largely due to the promising news regarding Remestemcel's ability to treat patients suffereing with the disease. In early May, the Mesoblast share price jumped 13% as it commenced trials of its COVID-19 treatment. The trial achieved an 83% survival rate and reported that 75% of patients managed to come off ventilator support within a ten day period.

Furthermore, Mesoblast's recent financial performance has also been strong. The company recorded a 113% increase in overall revenues to US$31.5 million for the first 9 months of FY 2020, compared to the prior corresponding period. Mesoblast also completed a $138million fund raising in May, adding to the strength of its balance sheet.

In a highlight for the company, it is currently awaiting a priority review of Ryoncil by the United States FDA for the treatment of children with steroid-refractory acute host disease.  The action date is 30 September 2020 and, if approved, Mesoblast will make Ryoncil immediately available in the US market.

Foolish takeaway

The Mesoblast share price has soared a huge 124% in the last year alone, pushing it into the S&P/ASX 200 Index (ASX: XJO). The company has been well placed to benefit from the onset of the pandemic which has been instrumental in fuelling its share price growth this year. Furthermore, since Ryoncil is awaiting registration later this year, and the decision is expected to have huge ramifications for the company's share price, I believe Mesoblast definitely deserves a place on your watchlist. 

Motley Fool contributor Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A man looking at his laptop and thinking.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a disappointing hump day session for the ASX today.

Read more »

Young man with a laptop in hand watching stocks and trends on a digital chart.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

Man with a hand on his head looks at a red stock market chart showing a falling share price.
Share Market News

Why A2 Milk, Boss Energy, Evolution Mining, and Lifestyle Communities shares are sinking

These shares are under pressure on hump day. But why?

Read more »

A young man talks tech on his phone while looking at a laptop. A financial graph is superimposed across the image.
Share Market News

Why Botanix, Dexus, Strickland, and Telix shares are charging higher today

Let's see why these shares are having a good session on hump day.

Read more »

A man sits in deep thought with a pen held to his lips as he ponders his computer screen with a laptop open next to him on his desk in a home office environment.
Share Market News

What does Macquarie think Origin Energy shares are worth?

Let's see what the broker is saying about this energy giant.

Read more »

A female sharemarket analyst with red hair and wearing glasses looks at her computer screen watching share price movements.
Broker Notes

Up 34% this year, can Challenger shares keep rising according to Macquarie?

The leading broker has released a new research note.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Share Fallers

Guess which ASX 200 stock is crashing 42% on big news

Big bad news is weighing heavily on this stock today.

Read more »

An analyst wearing a dark blue shirt and glasses sits at his computer with his chin resting on his hands as he looks at the CBA share price movement today
Opinions

Expert's verdict on 3 ASX 200 shares (2 have doubled in value and the other has lost 29%)

Two of these stocks were the best performers of their sectors in FY25. Should you buy, hold, or sell?

Read more »